To determine whether the results of the self-reported International Index of Erectile Function (IIEF) to assess erectile function can overestimate the degree of erectile impairment. A total of 32 consecutive patients seeking treatment for erectile dysfunction (ED) at a urologist's office were evaluated by completion of the erectile function domain of the IIEF. Nocturnal penile tumescence testing using the Rigiscan (Timm Medical Technologies Inc., USA) was performed in these patients after completion of the IIEF. The median IIEF-6 score was 9 of 30 (range, 1-25; mean, 11/30). Rigiscan results were abnormal in six patients (19%), normal in 25 patients (78%), and unable to interpret in one patient (3%). IIEF-6 scores were subdivided by severity along with Rigiscan results. There was no correlation between age, IIEF score, or Rigiscan results. In conclusion, the IIEF is a useful tool and is helpful for follow-up of a patient to evaluate efficacy of treatments for ED, but should not replace objective testing to diagnose the quality of ED.
Introduction
Numerous self-report measures used to assess erectile dysfunction (ED) have been developed. Initial interest for these questionnaires stemmed from differentiating psychogenic from nonpsychogenic ED. [1] [2] [3] The most widely used self-administered questionnaire, the International Index of Erectile Function (IIEF) or one of its derivatives, has been used widely in more than 50 clinical trials as the primary end point in evaluating the efficacy of sildenafil in various patient populations, as well as the most recently released oral phoshodiesterase-5 (PDE-5) inhibitors vardenafil and tadalafil. [4] [5] [6] The IIEF was developed in conjunction with, and as an adjunct to, the evaluation of clinical efficacy of the first oral PDE-5 inhibitor, sildenafil. 7 One reason for such widespread implementation of the IIEF in clinical trials lies in its cost effectiveness and its ability to allow drug companies a method to quantify treatment responses in a way that is presentable for Food and Drug Administration reviews. The IIEF was not developed as a diagnostic tool, but rather as a means to evaluate a treatment effecting in a longitudinal fashion. An important limitation of the IIEF is its inability to differentiate between specific causes of ED. 8, 9 Nocturnal penile tumescence (NPT) testing is able to quantify the normal physiologic erections that occur during sleep, primarily during rapid eye movement sleep. Nocturnal erections rely on intact corticospinal efferents as well as the vascular responsiveness of penile tissue to those signals. A nocturnal monitoring device measures the number of erectile episodes, tumescence, maximal penile rigidity, and duration. NPT is the only objective measure available to differentiate between the ability and inability to attain sustained penile rigidity, that is, psychogenic and organic ED. It is considered as one of the fundamental tools for evaluation and selection of appropriate management for patients. NPT is considered an essential research tool for objective assessment of pharmacologic therapies. However, its use and the use of other objective measures to evaluate erectile function largely have been supplanted by self-assessment questionnaires such as the IIEF. 10 The aim of the present study was to question the diagnostic accuracy of the current popular trend that uses the results of the IIEF for either prescribing one of the PDE-5 inhibiting drugs as first-line therapy or accepting the diagnostic score as an estimate of the true prevalence of ED.
Methods
All procedures and methods of data collection were approved by the Institutional Review Board before commencement of the study. Between February and November, 2003, 32 consecutive patients with a chief symptom of ED seeking treatment at the urologist's office were evaluated by history, physical examination, and completion of the erectile function domain of the IIEF, also known as the IIEF-6.
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An IIEF-6 score of less than 26 was considered abnormal. NPT testing using the Rigiscan with Rigiscan Plus software (Timm Medical Technologies Inc., USA) was performed in these patients after completion of the IIEF-6. The patients were instructed on proper use of the instrument. Baseline parameters were obtained and calibration was performed before the patients left the office. Data from two consecutive nights were obtained. Data collected from Rigiscan evaluation included tumescence activity units (TAU) and rigidity activity units (RAU) at the tip and the base, total number of events, best event time, and total time. The criterion used for a normal Rigiscan result was the finding of a single best event of more than 70% rigidity at the tip for more than 10 min. A Pearson's correlation was performed using GraphPad Prism software (GraphPad Software, San Diego, CA, USA) with regard to age, IIEF score, and Rigiscan results. A P-value of p0.05 was considered statistically significant.
Results
The median age of the study group was 40 years (range, 24-61 years; mean, 41 years). The median IIEF-6 score was 9 of 30 (range, 1-25; mean, 11 of 30). Comorbidities included diabetes mellitus in eight patients (25%), hypertension in nine patients (28%), and both diabetes and hypertension in five patients (16%). Rigiscan results using single best event were abnormal in six patients (19%), normal in 25 patients (78%), and unable to be interpreted in one patient (3%). IIEF-6 scores were subdivided by severity along with Rigiscan results, including average RAUs and TAUs at the tip of the penis, as shown in Table 1 . Pearson's correlation for age, r ¼ À0.181 (95% confidence interval (CI), À0.5082 to 0.1919; P ¼ n.s.). For IIEF score versus Rigiscan results, the average tip TAU was r ¼ 0.2856 (95% CI, À0.08337 to 0.5856; P ¼ n.s.), and the average tip RAU was r ¼ 0.229 (95% CI, À0.1432 to 0.5444; P ¼ n.s.). The average base TAU was r ¼ 0.2951 (95% CI, À0.07303 to 0.5924; P ¼ n.s.), and the average base RAU was r ¼ 0.2897 (95% CI, À0.07889 to 0.5886; P ¼ n.s.). There was no correlation between age, IIEF score, or Rigiscan results.
Comment
In the current accepted approach to the treatment of patients seeking treatment for ED is that the expected incidence of normal erectile function in is expected to be less than the 78% shown in this study. Thus, in a recent report using duplex ultrasound to assess penile blood flow after intracavernosal injection of alprostadil showed a normal vascular response in only 30 of 80 (38%) participants, all of whom had abnormal IIEF results. There was no correlation with severity of ED by IIEF score and results of duplex ultrasound in that study. 12 A limitation of this current report is that it is not population based. However, patients seeking treatment at a urologist's office were not chosen based on the suspicion of psychogenic impotence. Rather, they were consecutive patients who reported ED and underwent Rigiscan testing with the goal of eliminating selection bias on the part of the clinician. In the era of massive advertising for easily available 
International index of erectile function and objective studies A Melman et al oral remedies, the younger median age in our study than that of the typical patient population seeking treatment for ED can represent a selection bias on the part of today's patients requesting diagnosis and treatment. In the era before sildenafil, we reported on a population of patients of whom more than 60% were between 50 and 70 years of age, 13 which is a higher age than the patients in the present report. The difference may represent a consequence of the pressures of advertising on younger men to 'perform better' in their relationships.
Objective tools providing anatomic and physiologic data used to evaluate ED as part of the urologists' armamentarium both to diagnose a specific cause and to evaluate response to treatment include physical examination, NPT testing, plethysmography, neurophysiologic testing including warm thermal thresholds, Doppler ultrasound, pelvic angiography, and cavernosometry. [14] [15] [16] [17] [18] Each of these tools provide unique information with distinct indications and limitations, depending on the cause of ED suspected for an individual patient. Through the use of these tools, a more accurate assessment of the incidence and prevalence of specific causes can become apparent with properly designed trials. Adequate studies using appropriate subgroups then can be performed. With the advent of novel pharmacotherapy for ED, enrollment of a proper patient cohort will be necessary to explain why certain medications and treatment methods work in some patients and not in others.
NPT has been validated, and with development of the Rigiscan Plus software, which includes area-under-the-curve analysis with radial RAU measurements and TAU measurements and their corresponding nomograms, has produced a standardization that improves its sensitivity and specificity for accurate recognition of an erection that is of sufficient rigidity and duration for intercourse. Sensitivities and specificities of 42-85% and of 93-100%, respectively, have been reported. 17, 19, 20 The use of NPT is based on the concept that to produce a nocturnal erection, the corticospinal efferents to the penis and the vascular responsiveness of the penile tissue to those nerve signals must be intact. However, production of an erection in the context of sexual activity also requires normal responsiveness to sensory stimuli. The inability of NPT to evaluate impairment of afferent signals from the penis is an important limitation. Considering patients with normal results by Rigiscan data alone as having normal erectile function includes men with a sensory neurogenic cause and would contribute to specificities of less than 100%.
The introduction of sildenafil has increased public awareness and has enlightened public perceptions of ED as a medical condition. With increased media exposure and the subsequent increasing public awareness, there has been a shift in popular perceptions of ED. These new oral medications, with associated promotion, are changing ED from something embarrassing and rarely admitted to something quite common that is almost perceived as a normal part of aging.
The IIEF and other self-assessment questionnaires have been shown in previous studies to be unable to differentiate between various causes of ED. 21, 22 However, few clinical trials have been performed since the introduction of sildenafil in which the IIEF was not used as a primary end point. The target of the IIEF is the primary care provider. The Process of Care Model for the Evaluation and Treatment of ED segregates therapies as first line, second line, and third line. 23 First-line therapies include oral agents, vacuum erection devices, and couples or individual sex therapy. These are considered to be the realm of the primary care provider. Second-and third-line therapies include intraurethral and intracavernosal medications and the surgical placement of penile prostheses. Referral to a urologist is based on the need for these second-and third-line therapies, on the need or request for diagnostic testing or management, or both. In this paradigm, with increased use of the IIEF, management by the primary care provider, and the treatment of patients with psychogenic impotence as well as of ED resulting from other causes, treatment with PDE-5 inhibitors is likely to be maintained or increased.
This goal-directed approach, with the end being improved erectile function by administering oral treatments to patients who report ED, as substantiated by self-administered questionnaires such as the IIEF, imposes the inclusion of patients with various causes of ED. This model leads to prescription of medications incorrectly to a significant population of patients, when the medication does not match the cause of ED. In the case of psychogenic impotence, the drug may help alleviate the problem (lack of a sustained erection) for the wrong-stated reasons (physical cause of the problem).
We are now in an era of development of causespecific oral pharmacotherapy for ED. For example, research in the realm of gene therapy includes gene therapy and transfer of nitric oxide synthases, growth factors, cytokines, brain-derived neurotrophic factors, neurotransmitters, or enzymes as well as gene therapy and transfer to effect myocyte excitability and sensitization. 24 Ion channel gene therapy uses potassium channels to effect voltagegated calcium channels through hyperpolarization, increasing the responsiveness of corporal smooth muscle to endogenous smooth muscle relaxants. The maxi-K channel, currently in phase I testing, has shown effectiveness up to 6 months after intracavernosal injection in the rat model. [24] [25] [26] By targeting enzymes that effect smooth muscle dilatation and increase penile blood flow, the oral PDE-5 inhibitors are cause-specific treatments of vasculogenic ED. Dopamine receptor agonists such as the With the development of mechanism-specific medications for ED, entry studies need to assure that the target population studied has the type of ED that the medication is proposed to treat. Objective measures are needed to select these patients properly for clinical trials to determine efficacy accurately. The current data suggest that pen-and-pencil, self-administered tests are not sufficiently accurate to assess the problem.
Conclusions
Although the IIEF is a useful tool and is helpful for follow-up of a patient to evaluate efficacy of treatments for ED, it should not replace objective testing. Careful history and physical examination of both the patient and his sexual partner are necessary. 22, 23 The results of this paper are a caution of overdependency on the results from subjective data. Rigorous statistical methods using subjective data do not equate with the results obtained from objective testing.
